Disclosures: Jeffrey Teckman: Arrowhead Inc: Grant/Research Support, BioMarin: Consultant, Camp4: Grant/Research Support, Congruence Therapeutics: Consultant, Critical Path Institute: Consultant, Inhibrix: Grant/Research Support, KorroBio: Consulting, Takeda: Consultant, UniQure: Independent Contractor, Vertex: Consultant, Intellia: Consultant, Beam Therapeutics: Consultant, Alpha-1 Foundation: Grant recipient, Catherine Spino: Nothing to Disclose, Suiyan Huang: Nothing to Disclose, Gregor Horvath: Nothing to Disclose, John Magee: Nothing to Disclose, Philip Rosenthal: Nothing to Disclose 587 S100A8/9 IS UPREGULATED IN PLATELETS AND PLATELET-DERIVED MICROPARTICLES IN ALCOHOL-ASSOCIATED HEPATITIS AND CAN MEDIATE ENDOTHELIAL INFLAMMATION Fallyn Kirlin 1 Rolando Garcia-Milian 2 Yohan Kim 3 Fabrice Lucien-Matteoni 3 John Hwa 1 Enis Kostallari 3 Yasuko Iwakiri 2 Matthew McConnell 2 , 1 Yale University School of Medicine, 2 Yale University, 3 Mayo Clinic Rochester Background: Platelets have emerged as playing a pathological role in a variety of liver diseases, but their specific role in alcohol-associated hepatitis (AH) remains unknown

Aim for 23 liters of water per day, especially if you are experiencing nausea, vomiting, or diarrhea
Kushner is also wary of compounded versions, now that shortages have eased, because there's no way to be sure what's in the vial
What the Clinical Evidence Actually Supports About GLP-1 Medications and Weight Management Quick Answer: Omzo GLP-1 is a telehealth platform - not a drug itself
The evoke and evoke+ trials were large, rigorous, and well-designed
To demonstrate that a treatment truly works and is safe, researchers would need randomized clinical trials, clear dosing standards, and ongoing safety monitoringthe same safeguards used before any medication is approved for medical use